Company: PMVP
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030414
Chunk: 167

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 167
---

    )

    Cash, cash equivalents, and restricted cash

    Cash, cash equivalents, and restricted cash - beginning of period

    38,528

    109,119

    173,289

    Cash, cash equivalents, and restricted cash - end of period
     
    $
    40,876

    $
    38,528

    109,119

    Supplemental disclosures of noncash investing activities

    Accrued purchases of property and equipment
     
    $
    —

    $
    6

    $
    196

The accompanying notes are an integral part of these consolidated financial statements.

 107

PMV Pharmaceuticals, Inc.

Notes to Consolidated Financial Statements

1.  Formation and Business of the CompanyOrganizationPMV Pharmaceuticals, Inc. (the “Company”) was incorporated in the state of Delaware in March 2013. Since inception, the Company has devoted substantially all of its time and efforts to performing research and development activities and raising capital. The Company is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The Company’s headquarters are located at 400 Alexander Park Drive, Suite 301, in Princeton, New Jersey.The Company is subject to risks and uncertainties common to clinical stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.The Company has incurred net losses and negative cash flows from operations since its inception. During the year ended December 31, 2024, the Company incurred a net loss of $58,709 and used $51,282 of cash for operations. As of December 31, 2024, the Company had an accumulated deficit of $368,712.  Cash, cash equivalents, and marketable securities were $183,297 as of December 31, 2024. Management expects to incur substantial additional operating losses for the next several years and may need to